Samuel Watson

Wilbanks, Smith & Thomas Asset Management LLC (WST) is a SEC-registered asset management firm headquartered in Norfolk, Virginia. In 2024, the firm was acquired by Clearstead Advisors LLC, a holding company. The firm was founded by Wayne Wilbanks in 1990. WST provides investment services for individuals, pension and profit-sharing plans, corporations, Taft Hartley organizations, municipalities, bank trust departments, trust companies, insurance companies, foundations, and endowments.

Technology Business Research, Inc. (TBR) is an independent investment research firm headquartered in Hampton, New Hampshire. The firm was founded in 1996 and they specialize in providing in-depth and timely insights within the computer, software, telecommunications, mobility and professional services industries. TBR’s proprietary process is based on highly-focused research, company-centric data and expert analysis.

Mallinckrodt Medical, Inc. manufactures and markets healthcare products. Its products include contrast media & delivery systems, radiology imaging products, radiopharmaceuticals and urology imaging systems. The company is headquartered in Pointe-Claire, Canada.

Technology Alliance supports and promotes technology-based businesses and research institutions. It organizes programs, events, data analysis, and policy activities for education, research, and entrepreneurship technology advancement. The company was founded by William H. Gates Sr. in 1996 and is headquartered in Seattle, WA.

Arzeda Corp. operates as a synthetic biology company. It works thru agriculture, functionalized sweeteners and ingredients, chemicals and materials, and pharmaceuticals and diagnostics. The company was founded by Eric Althoff, David Baker, Daniela Grabs-R?thlisberger, Michael A. Martino and Alexandre Zanghellini in 2008 and is headquartered in Seattle, WA.

Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA.

HemaFlo Therapeutics, Inc. is an American private company that develops drag-reducing polymers (DRP) to improve blood flow in acute and chronic conditions associated with decreased tissue perfusion. DRPs are administered intravenously and work mechanically to reduce friction in flowing blood and stimulate blood vessel dilation, resulting in improved blood flow without increasing blood pressure. The CEO of the company is Michael A. Martino.